Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001144204-13-061797
Filing Date
2013-11-14
Accepted
2013-11-14 15:54:43
Documents
11
Period of Report
2013-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q v359117_10q.htm 10-Q 605480
2 EXHIBIT 31.1 v359117_ex31-1.htm EX-31.1 11429
3 EXHIBIT 31.2 v359117_ex31-2.htm EX-31.2 11264
4 EXHIBIT 32.1 v359117_ex32-1.htm EX-32.1 6814
5 EXHIBIT 32.2 v359117_ex32-2.htm EX-32.2 8025
  Complete submission text file 0001144204-13-061797.txt   3023490

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT tglp-20130930.xml EX-101.INS 334058
7 XBRL TAXONOMY EXTENSION SCHEMA tglp-20130930.xsd EX-101.SCH 37054
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE tglp-20130930_cal.xml EX-101.CAL 31965
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tglp-20130930_def.xml EX-101.DEF 159328
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE tglp-20130930_lab.xml EX-101.LAB 195612
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tglp-20130930_pre.xml EX-101.PRE 193437
Mailing Address 125 MAIDEN LANE, SUITE 309 NEW YORK NY 10038
Business Address 125 MAIDEN LANE, SUITE 309 NEW YORK NY 10038 212-797-9877
Tongli Pharmaceuticals (USA), Inc. (Filer) CIK: 0001052284 (see all company filings)

EIN.: 841090791 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-52954 | Film No.: 131219791
SIC: 2834 Pharmaceutical Preparations